Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.42 |
| ▸ | CDC25B | P30305 | 6/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910414 | 0.90 | PTPN1 (0.41) | PTPN1CDC25BTNFPTPN2PTPN6 | |
| SCHEMBL2910417 | 0.90 | PTPN1 (0.41) | PTPN1CDC25BTNFPTPN2PTPN6 | |
| SCHEMBL18744567 | 0.85 | NT5E (0.51) | PTPN1CDC25BTSHRPTPN2PTPN6 | |
| SCHEMBL18241576 | 0.85 | NT5E (0.51) | PTPN1CDC25BTSHRPTPN2PTPN6 | |
| SCHEMBL20295300 | 0.85 | NT5E (0.51) | PTPN1CDC25BTSHRPTPN2PTPN6 | |
| SCHEMBL8225871 | 0.85 | NT5E (0.51) | PTPN1CDC25BTSHRPTPN2PTPN6 | |
| SCHEMBL4181388 | 0.85 | NT5E (0.51) | PTPN1CDC25BTSHRPTPN2PTPN6 | |
| SCHEMBL2482599 | 0.85 | NT5E (0.51) | PTPN1CDC25BTSHRPTPN2PTPN6 | |
| SCHEMBL19731824 | 0.85 | NT5E (0.51) | PTPN1CDC25BTSHRPTPN2PTPN6 | |
| SCHEMBL17502058 | 0.82 | TSHR (0.59) | PTPN1CYP2D6ALDH1A1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003260-A1 | Solid-Phase and Solution-Phase Synthesis of Glycosylphosphatidylinositol Glycans | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003260-A1 | Solid-Phase and Solution-Phase Synthesis of Glycosylphosphatidylinositol Glycans | GPI, ALG1, FUT5 | PTPN1 3606/4885CDC25B 534/4885CYP2D6 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.